Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of ZEPATIER (elbasvir and
grazoprevir), an investigational, once-daily, fixed-dose combination
tablet for the treatment of chronic hepatitis C virus (HCV) in adult
patients. The CHMP positive opinion will be reviewed by the European
Commission.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more